The estimated Net Worth of Michael Douglas Taylor is at least $5.39 Million dollars as of 3 May 2021. Michael Taylor owns over 8,000 units of Deciphera Pharmaceuticals Inc stock worth over $204,720 and over the last 7 years he sold DCPH stock worth over $0. In addition, he makes $5,181,090 as Director at Deciphera Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Michael Taylor DCPH stock SEC Form 4 insiders trading
Michael has made over 22 trades of the Deciphera Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of DCPH stock worth $26,720 on 3 May 2021.
The largest trade he's ever made was exercising 125,000 units of Deciphera Pharmaceuticals Inc stock on 1 October 2020 worth over $236,250. On average, Michael trades about 25,271 units every 30 days since 2017. As of 3 May 2021 he still owns at least 8,000 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Michael Taylor stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Taylor biography
Dr. Michael Douglas Taylor serves as Director of the Company. He is an Operating Partner with Mission BioCapital, an early-stage life science venture fund. Dr. Taylor served as our President and Chief Executive Officer from March 2014 until his retirement as Chief Executive Officer in March 2019. Dr. Taylor served as Senior Advisor to Deciphera from March 2019 through September 2019. Prior to joining Deciphera, Dr. Taylor was Chief Executive Officer of Ensemble Therapeutics, Corp., a small molecule drug discovery company, from July 2007 to October 2013. Prior to joining Ensemble, Dr. Taylor was Senior Vice President for Pfizer Inc.’s Global R&D division and served as Vice President, Drug Development at Warner-Lambert/Parke-Davis, where he led early and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin®. Dr. Taylor has authored or co-authored 65 manuscripts and published abstracts and is co-inventor on eight patents. Dr. Taylor holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo School of Pharmacy, was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania, and holds a B.S. magna cum laude in chemistry from the University of South Florida.
What is the salary of Michael Taylor?
As the Director of Deciphera Pharmaceuticals Inc, the total compensation of Michael Taylor at Deciphera Pharmaceuticals Inc is $5,181,090. There are 1 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
How old is Michael Taylor?
Michael Taylor is 65, he's been the Director of Deciphera Pharmaceuticals Inc since 2019. There are 3 older and 13 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
What's Michael Taylor's mailing address?
Michael's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Insiders trading at Deciphera Pharmaceuticals Inc
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
What does Deciphera Pharmaceuticals Inc do?
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
What does Deciphera Pharmaceuticals Inc's logo look like?
Complete history of Michael Taylor stock trades at Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc executives and stock owners
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Steven Hoerter,
President, Chief Executive Officer, Director -
Michael Taylor,
Director -
Matthew Sherman,
Executive Vice President, Chief Medical Officer -
Thomas Kelly,
Chief Financial Officer, Executive Vice President, Treasurer -
Steven L. Hoerter,
Pres, CEO & Director -
Daniel Flynn,
Founder, Executive Vice President, Chief Scientific Officer -
Dr. Matthew L. Sherman,
Exec. VP & Chief Medical Officer -
Ron Squarer,
Independent Director -
Frank Friedman,
Independent Director -
Thomas Patrick Kelly J.D.,
Exec. VP, CFO & Treasurer -
Dr. Matthew L. Sherman M.D.,
Exec. VP & Chief Medical Officer -
Dr. Daniel L. Flynn,
Exec. VP, Chief Scientific Officer & Founder -
Daniel C. Martin,
Sr. VP & Chief Commercial Officer -
Dr. Stephen B. Ruddy Ph.D.,
Sr. VP & Chief Technical Officer -
Susan Kelley,
Independent Director -
James Bristol,
Independent Chairman of the Board -
Edward Benz,
Independent Director -
Patricia Allen,
Independent Director -
Dennis Walsh,
Independent Director -
John Martin,
Independent Director -
Melissa Forst,
IR Contact Officer -
Lisa Amaya Price,
Sr. VP & Chief HR Officer -
Jennifer Larson,
Sr. VP of Fin. & Investor Relations -
Margarida Duarte,
Sr. VP & Head of International -
Jama Pitman,
Sr. VP of Regulatory, Quality & Portfolio Management -
Jeffrey M. Held J.D.,
Sr. VP & Gen. Counsel -
Jennifer Robinson,
VP of Investor Relations -
Dashyant Dhanak,
EVP & Chief Scientific Officer -
Leaf Venture Management Iii...,
-
Liam Ratcliffe,
Director -
Associates Llc Brightstar,
10% owner -
Christopher John Morl,
Chief Business Officer -
Michael Jay Ross,
Director -
Oliver Rosen,
Chief Medical Officer -
Stephen B. Ruddy,
Chief Technical Officer -
Daniel C. Martin,
Chief Commercial Officer -
Jama Pitman,
SVP, Chief Development Officer